Background: In order to define the role of the human cytomegalovirus (HCMV) small terminase subunit pUL89, analysis by RNA interference was applied. Methods: Cell lines expressing pUL89-specific short hairpin RNAs (shRNAs) were constructed by transduction of shRNAs via infection with retroviral vectors. These cell lines were infected with HCMV AD169 and were analysed for pUL89 expression, viral yield, plaque reduction, amount of viral DNA and particle formation. Results: After infection of the cell lines with HCMV, the expression of pUL89 was reduced by up to 86% for shRNA_A and 84% for shRNA_B at the later time points of infection. Cell lines expressing shRNA_C and the control had no effect on the pUL89 expression level. In addition, the inhibitory effect corresponded to a decrease in viral growth kinetics, viral DNA and plaque formation. Analysis by electron microscopy demonstrated that infection of cells expressing pUL89-specific shRNA_A and shRNA_B resulted in a complete inhibition of viral particle formation. Conclusions: HCMV is a serious life-threatening opportunistic pathogen in immunocompromised patients. Because of multiple problems caused by the current available drugs, development of new strategies are needed. Our data clearly demonstrate that pUL89-specific shRNAs mediated the inhibition of formation of replicative infectious particles and therefore represent a new promising mechanism for antiviral therapy against HCMV infection.
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Human cytomegalovirus (HCMV), one of eight human herpesviruses, can cause serious illness in neonates as well as in immunocompromised adults. Transplant and AIDS patients, for example, might develop life-threatening diseases as a consequence of primary infection or reactivation of latent infection. Additionally, HCMV infections are also associated with congenital neurological complications. The current drugs (such as acyclovir, ganciclovir, cidofovir and foscarnet) have limited effects, often exhibit dose-dependent toxicity and cause additional complications, including drug resistance. Considering that present therapeutical approaches are limited, new strategies, which might benefit from a better understanding of viral molecular biology, are needed. This, in turn, would necessitate the characterization of new targets supporting different modes of action. To this end, an active interference with the cleavage and packaging mechanisms of viral DNA might offer viable alternatives.
Herpesvirus replication occurs as a rolling circle replication leading to concatemers, which are head-totail linked unit-length genomes. The genome contains the so-called a sequence that is located at both terminal repeats and in opposite orientation between the L-and S-segments [1, 2] . The a sequence contains specific motifs, pac1 and pac2. These motifs are necessary for cleavage of concatemers into unit-length genomes and packaging into preformed capsids [3] . Enzymes involved in the viral DNA packaging process are responsible for site-specific duplex nicking and insertion of DNA into procapsids [4, 5] . These enzymes, so-called terminases, were first described for doublestranded DNA bacteriophages and are highly conserved throughout many double-stranded DNA viruses, herpesviruses and adenoviruses. Terminases are responsible for the packaging of unit-length genomes into the interior of procapsids. They represent multifunctional hetero-oligomers: one protein catalyses the ATPdependent translocation into preformed capsids and the other induces cleavage of DNA concatemers into unit-length genomes [6] [7] [8] [9] . The following six steps are
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Short hairpin RNAs specific to human cytomegalovirus terminase subunit pUL89 prevent viral maturation Introduction involved in this process: the recognition of viral DNA by a specific protein, the binding of the protein to the DNA at specific sequence motifs (packaging signals, for example, pac1 and pac2), the translocation of the DNA-protein complex to the procapsid, the interaction of the DNA-protein complex with the portal protein, the import of one unit-length genome into the capsid (involving ATP hydrolysis by one terminase subunit) and the completion of the packaging process by cleavage of excess DNA (two-strand nicking). Recently, we have demonstrated that the HCMV terminase consists of two subunits, the large one encoding pUL56 and the small one encoding pUL89 [10] [11] [12] , where each protein has a different function. Although it is supposed that the large terminase subunit pUL56 mediates specific binding to packaging elements (the so-called pac motifs) on the concatemers, provides energy for translocation of the DNA to the procapsids and associates itself with the capsid for enabling the entry of the DNA, the small subunit pUL89 seems to be mainly required for cleavage of concatemeric DNA into unit-length genomes [13] [14] [15] [16] .
In order to define the role of pUL89 for viral replication RNA interference (RNAi) was performed. It has been demonstrated that small interfering RNAs (siRNAs) are able to silence genes in vivo. These double-stranded siRNAs are incorporated into a silencing complex called RISC, which binds messenger RNA (mRNA) with a complementary sequence and then cuts the homologous region [17, 18] . The resulting instable mRNA is degraded, leading to a reduction in expression of the target gene. In this study, we identified pUL89-specific short hairpin RNAs (shRNAs) and established stable shRNA-expressing cell lines by transducing lentiviral vectors to human foreskin fibroblasts (HFFs). These cell lines enabled us to analyse the long-term antiviral effect in the viral life cycle.
Methods

Cells and virus
HFF or 293T cells (European Collection of Cell Cultures, Salisbury, UK) were grown in Dulbecco's minimal essential medium (DMEM) supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, penicillin (5 U/ml) and streptomycin (50 µg/ml). HFF cells at passages 10-15 were used for infection and experiments were carried out with confluent cell monolayers (1.5×10 7 cells). Infection of HFF cells with HCMV AD169 was carried out as described previously [12] .
Plasmid construction
For direct detection of cells containing the gene silencing construct, enhanced green fluorescent protein (EGFP) together with an internal ribosome entry site (IRES) were inserted after the puromycin-resistant gene into the vector pSIREN-RetroQ (BD Bioscience Clontech, Heidelberg, Germany), yielding pSIREN-RetroQ-EGFP (provided by Frank Neipel, Virologisches Institut, Klinische und Molekulare Virologie, Universitätsklini-kum Erlangen, Erlangen, Germany). The RNAi-Ready pSIREN-RetroQ-EGFP vector (provided by Frank Neipel) was used to clone double-stranded oligonucleotides encoding UL89-specific shRNA. The shRNA oligonucleotides were designed with 19 bases of sense and antisense strands (Table 1 ) separated by a hairpin loop (TTCAAGAGA), a 6 nucleotide poly(T) terminal sequence, followed by the sequence for XhoI restriction according to the manufacturer's instructions (BD Bioscience Clontech). Single-stranded sense and antisense shRNA oligonucleotides were synthesized (Biomers.net, Ulm, Germany) and both strands were annealed prior to ligation into pSIREN-RetroQ-EGFP. As a negative control, scrambled shRNA oligonucleotide (shRNA_sc) was inserted into pSIREN-RetroQ-EGFP ( Table 1) .
Transfection of shRNA expression plasmid
For transient expression, 293T cells (5×10 6 ) were seeded on 10 cm diameter dishes. 293T cells at 90% confluency were transfected with pSIREN-RetroQ-EGFP, pSIREN-RetroQ-EGFP-shRNA_A, -shRNA_B, -shRNA_C and -shRNA_sc together with pcDNA-UL89 by the Metafectene PRo method (Biontex, Martinsried, Germany). As a control, pcDNA-UL89 was cotransfected with pHM829 (expressing EGFP). The transfection efficiency was monitored by green fluorescent protein fluorescence. Cells were harvested at 40 h post-transfection and subjected to western blot analyses.
Western blot analyses
Extracts from mock-infected, infected or transfected cells were separated on 10% (w/v) polyacrylamide gel and transferred to nitrocellulose sheets and subjected 
shRNA, short hairpin RNA.
to western blot analyses as described previously [19] . The pAbUL89 antibody (1:10 [16] ) specific for pUL89 and monoclonal antibodies CH167 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), BS510 (provided by Bodo Plachter, Institute of Virology, Johannes Gutenberg-University Mainz, Mainz, Germany), 27-156 and 28-4 (both provided by William J Britt, University of Alabama, Birmingham, AL, USA) specific for pUL57, pUL44, glycoprotein B (gB) and major capsid protein (MCP), respectively, were used as the primary antibody prior to incubation with horseradish peroxidase-conjugated anti-human F(ab′) 2 fragments (1:5,000 in 3% bovine serum albumin; Biozol, Eching, Germany). The membranes were reprobed with an antibody against β-actin (1:5,000; Biozol) and horseradish peroxidaseconjugated anti-mouse F(ab′) 2 fragments (1:5,000; Biozol) to verify equal loading. Detection of protein bands was performed by using ECL reagent as recommended by the supplier (Thermo Fisher Scientific, Bonn, Germany). The obtained signals were quantified using a BioImager and AIDA software (Raytest, Straubenhardt, Germany). The values were calculated by subtracting background level from each probe. The values of shRNA_sc were set to 100%.
Lentivirus production and construction of expression cell lines
For construction of retroviral virions, plasmids pHIT60 encoding for the MLV gag and pol proteins (provided by Klaus T Überla, Ruhr University Bochum, Bochum, Germany), and pVSV-G encoding the vesicular stomatitis virus G-protein [20] were used. Aliquots of 4.5 µg pHIT60, 4.5 µg pVSV-G and 3 µg pSIREN-RetroQ-EGFP-shRNA_A, -shRNA_B, -shRNA_C, -shRNA_sc or vector alone were cotransfected into 293T cells (5×10 6 cells). The medium was replaced 24 h after transfection with fresh medium containing 10% FCS. The supernatant containing retroviruses was harvested at 48 h post-transfection.
HFF cells (8×10 4 ) were infected with supernatant of retroviruses to introduce shRNAs of UL89 shRNA_A, shRNA_B, shRNA_C or shRNA_sc. The cells were grown in the presence of puromycin (CAS 58-58-2; 5 µg/ml). Stable clones were obtained after 1 week of selection.
Growth characteristics HFF cells (8.5×10
4 cells per well) expressing shRNA_A, shRNA_B, shRNA_C or shRNA_sc were seeded in 24-well culture plates. Confluent cells were infected with HCMV AD169 at a multiplicity of infection (MoI) of 3. At 0, 24, 48, 72, 96 and 120 h post-infection, the supernatants were removed from the well and frozen at -80°C. After collection at all time points, the supernatants were thawed, transferred to 24-well plates with HFF cells on coverslips and the titres were determined by detection of immediate-early protein 1 (IE1; using the antibody mAbE13; Biozol) expression with indirect immunofluorescence.
Plaque reduction assays
Cell lines expressing shRNA_A, shRNA_B, shRNA_C or shRNA_sc were seeded in 24-well plates and infected with HCMV AD169 at a MoI of 0.1 in DMEM with 10% FCS. At 1 h post-infection, the inoculum was replaced with 2 ml methyl cellulose (Methocel MC; Fluka, Heidelberg, Germany) containing DMEM and 3% FCS. After incubation for 8 days at 37°C, the cells were stained with 0.1% crystal violet (in 20% ethanol) for 2 min and air dried prior to rinsing in distilled water. Plaques were counted using a microscope. Effects of the shRNAs were calculated by comparing shRNAexpressing cells with control wells.
Preparation of DNA
For quantification of viral DNA, HFF cells (3×10 6 cells per T-75cm 2 flask) expressing shRNA_A, shRNA_B, shRNA_C or shRNA_sc were infected with HCMV AD169 at a MoI of 1. At 4 days post-infection, cells were harvested and DNA was isolated using a MagNA Pure LC DNA Isolation kit (Roche, Basel, Switzerland) in an automated MagNA Pure LC apparatus (Roche) according to the instructions from the supplier. DNA was eluted in 100 µl elution buffer (Roche).
Real-time quantitative PCR
Amounts of viral DNA were determined by quantification of real-time PCR. oligonucleotides (for real-time PCR) amplifying the HCMV major immediate early gene (MIE; exon 4) and albumin were synthesized by Eurogentec (Köln, Germany) The primers for MIE were 5′-AAGCGGCCTCTGATAACCAAG-3′ (forward) and 5′-GAGCAGACTCTCAGAGGATCGG-3′ (reverse), and for albumin were 5′-GTGAACAGGCGACCATGCT-3′ (forward) and 5′-GCATGGAAGGTGAATGTTTCAG-3′ (reverse). Multiplex PCR was performed using 10 µl of DNA, 25 Thin-sectioning and electron microscopy HFF cells (1×10 6 ) expressing shRNA_A, shRNA_B, shRNA_C or shRNA_sc were seeded in 25 cm 2 flasks and infected with HCMV AD169 at a MoI of 3. Cells were fixed at 96 h post-infection and embedded as described previously [21, 22] . Sections were analysed using a Tecnai TM G2 (FEI Company, Eindhoven, the Netherlands) electron microscope operated at 120 kV.
Biostatistical analyses
In order to determine the efficiency of the shRNAs on the decrease in DNA, plaque formation and western blot, statistical analyses were performed. The results obtained from paired Student's t-test were used to calculate significance. A P-value of ≤0.05 was considered significant.
Results
Suppression of pUL89 gene expression
In order to identify the efficiency of gene silencing of the chosen shRNA sequences, recombinant pSIREN-RetroQ-EGFP vectors containing either UL89 shRNA_A, shRNA_B or shRNA_C were cotransfected with a pUL89 expression vector (pcDNA-89) or the vectors pcDNA-89 or pSIREN-RetroQ-EGFP were transfected alone. In the cells, shRNAs were converted into siR-NA-like molecules, initiating RNAi. The expression of pUL89 was knocked down in the presence of shRNA_A, shRNA_B or shRNA_C (Figure 1, lanes 4-6) . only in cells transfected with the UL89-encoding vector was the protein detected ( Figure 1, lane 3) . Untransfected cells (mock) or pSIREN-RetroQ-EGFP vector transfected cells served as controls (Figure 1, lanes 1-2) . These observations demonstrated that all shRNAs at least partially silence pUL89 expression.
Reduction of viral growth by shRNAs
To determine the effects of the UL89-specific shRNAs on viral replication, growth curves were performed after infection of shRNA-expressing cell lines with HCMV AD169. At 0, 24, 48, 72, 96 and 120 h post-infection, the supernatants were harvested and transferred to 293T cells (5×10 6 ) at 90% confluency were transfected with pSIRENRetroQ-enhanced green fluorescent protein (EGFP; pSIREN-EGFP), pSIRENRetroQ-EGFP-shRNA_A (shRNA_A), -shRNA_B (shRNA_B) and -shRNA_C (shRNA_C) together with pcDNA-UL89 by the metafectene PRO method (Biontex, Martinsried, Germany). Cells were harvested at 40 h post-transfection and subjected to western blot analysis with the antibody pAbUL89. As a loading control, the immunoblot was consecutively stained with an antibody against β-actin. The arrow indicates the position of pUL89. The molecular weight markers (M) are shown. shRNA, short hairpin RNA. shRNA_A-, shRNA_B-, shRNA_C-and shRNA_sc-expressing cell lines were infected with human cytomegalovirus (HCMV) AD169 at multiplicity of infection of 3. At each time point, cells and supernatants were harvested and progeny virus titres were determined by plaque reduction assay. Error bars on the histogram indicate the standard deviation from three independent experiments. PFU, plaque-forming units; shRNA, short hairpin RNA.
uninfected HFF cells (Figure 2 ). Titres were determined by detection of IE1 expression by using indirect immunofluorescence. shRNA_A and shRNA_B had the capacity to reduce virus release up to approximately 64% at 120 h post-infection for shRNA_A and at 72 h postinfection for shRNA_B (Table 2) , whereas shRNA_C and the control shRNA_sc had no effect on viral replication ( Figure 2 and Table 2 ). Taken together, the data presented suggested that the UL89-specific shRNAs were able to reduce particle release by >40%.
Influence of shRNAs on virus yield
Plaque assays were carried out to analyse the ability of shRNAs to reduce virus yield. Both UL89-specific shRNA_A and shRNA_B were able to reduce the plaque formation by >50% (Table 3) , whereas the number of plaques in the presence of shRNA_C was not effected (Table 3) . Cells infected in the presence of shRNA_sc served as control (Table 3 ). These results showed that both specific shRNAs have the ability to reduce virus yield, but could not abolish it. The significance of the results was determined by using paired Student's t-test.
Effect on de novo synthesis of viral DNA
In order to investigate whether RNAi has an effect on de novo DNA synthesis, quantitative real-time PCR analysis was performed. Cell lines expressing shRNA_A, shRNA_B, shRNA_C and shRNA_sc were infected with HCMV AD169 at a MoI of 1. After harvesting the cells at 96 h post-infection, the DNA was extracted and used for quantification of MIE copy numbers. The shRNA_C and shRNA_sc had no significant effect on MIE copy numbers (Table 3) . By contrast, cells expressing shRNA_A and shRNA_B led to a reduction of up to approximately 72% (Table 3 ). The significance of these results was determined by using paired Student's t-test. Taken together, our analysis demonstrated that the shRNA_A and shRNA_B resulted in a strong reduction of de novo viral DNA synthesis.
Efficient inhibition of pUL89 expression by shRNAs after infection
To examine whether UL89-specific shRNA can inhibit pUL89 expression, stable shRNA_A, shRNA_B, shRNA_C or scrambled shRNA (shRNA_sc) expression cell lines as well as HFF cells were infected with HCMV AD169 at a MoI of 3 or left uninfected (mock). Western blot analyses were performed to define the amount of pUL89 (Figure 3) . Interestingly, protein expression decreased during infection, starting with only marginal reduction at 48 h post-infection. (Figure 3A and 3B) and ending with a reduction of ≥80% at 120 h post-infection ( Figure 3 ). In detail, at 72 h post-infection, the suppression of pUL89 was 50% for shRNA_A and 59 for shRNA_B ( Figure 3B and 3F) ; at 96 h post-infection, 56% for shRNA_A and 75% for shRNA_B ( Figure 3C and 3G) ; and at 120 h postinfection, approximately 86% for shRNA_A and 84% for shRNA_B ( Figrue 3D and 3H ). In the presence of the control shRNA (shRNA_sc) as well as shRNA_C and in mock-infected cells, no obvious effect on UL89 gene expression was detected ( Figure 3A , 3B, 3C and At (A) 48, (B) 72, (C) 96 and (D) 120 h post-infection, cell extracts were subjected to 10% SDS-PAGE. The separated probes were transferred onto nitrocellulose prior to immunoblot analysis using the antibody pAbUL89. As a loading control, the immunoblot was consecutively stained with an antibody against β-actin. Specifically, the detected proteins were quantified using bioimaging analysis. protein, pUL57, processivity factor and pUL44) or late HCMV proteins (gB and MCP) were not affected (Additional file 1).
Influence on particle formation in infected cells
In order to determine the formation of particles, ultrathin sections of stable shRNA_A, shRNA_B, shRNA_C or scrambled shRNA expression cell lines infected with HCMV AD169 at a MoI of 3 were examined by electron microscopy (Figure 4) . In cell lines expressing shRNA_sc as well as shRNA_C, all types of capsids were found in the nuclei ( Figure 4E and 4G ). In addition, infectious particles (virions) as well as non-infectious deficient enveloped particles (so-called dense bodies) were observed in the cytoplasm or in the extracellular space ( Figure 4F and 4H) . By contrast, shRNA_A-and shRNA_B-expressing cell lines lead to an increase of B-capsids (precursor capsids with a scaffold) and a reduction of A-capsids (capsids lost DNA during packaging) and C-capsids (mature DNA-containing capsids; Figure 4A and 4C). In the cytoplasm, only dense bodies were observed ( Figure 4B and 4D). These results demonstrated that shRNA_A as well as shRNA_B prevent infectious particles formation.
Discussion
It has been shown that RNAi is an important function for cells to specifically down-regulate or silence gene expression [18, 23] . This system is therefore discussed as a new promising approach to analyse gene functions and for use in new antiviral strategies [24] . In this study, we used plasmid-based UL89-specific shRNAs mediating specific RNA silencing [23, [25] [26] [27] [28] . The advantage of this plasmid-based system is the continuous intracellular synthesis of shRNA resulting in constant siRNA levels over a long period of time. In this study we selected stable knockdown HFF cell lines by using lentiviral plasmid-encoded shRNAs. Infection of stable expression shRNAs cell lines with HCMV leads to an inhibition of pUL89 expression. This effect increased over time of infection with a reduction of >85% for shRNA_A and 84% for shRNA_B at 120 h post-infection, whereas shRNA_C did not lead to a remarkable reduction. With carefully controlled experiments using cell lines expressing scrambled shRNAs (shRNA_sc), we demonstrated that these effects were sequence-specific. The two promising shRNAs were analysed by electron microscopy to determine the phenotype in cell culture. Similar to our analysis with portal protein pUL104-specific shRNA [29] , the amounts of C-capsids were clearly reduced, thus leading to the inhibition of viral particle formation. Furthermore, we have shown that a potent knockdown of pUL89 resulted in a significant block of de novo DNA synthesis of the major IE1 gene. Previously we have shown that the HCMV terminase subunit pUL89 is essential for cleavage and for packaging of viral DNA into preformed capsids [10, 14, 16] ; therefore, the stable knockdown of pUL89 reveals its essential role in viral replication.
The terminase subunit pUL89 is one of the best conserved herpesvirus proteins. McGeoch et al. [30] reported that the protein leads to numerous homologues not only throughout mammalian herpesvirus but in addition to vertebrate ones. The most prominent homologue is the herpes simplex virus type-1 gene product of UL15 [31] . It has been demonstrated that this protein is also essential for viral replication and is, during this process, associated with the procapsid [31] [32] [33] . In almost every case for essential proteins, deletions resulted in lethal non-replicating phenotypes; therefore, RNAi is the best approach to study essential genes. In addition, RNAi has been discussed to be a potent tool in antiviral therapy against persistent virus infections. This treatment needs to be a stable gene therapy in order to protect cells against viral maturation [34] . For this aim, an approach with shRNAs that are constantly expressed intracellularly is a promising tool for treatment of persistent infections.
A problem for RNA viruses, such as HIV type-1 (HIV-1), occurs after prolonged cultivation of infected T-cells expressing shRNAs because escape viruses appear [35, 36] . This obstacle has been overcome by using only partially target sequences for anti-HIV-1 shRNAs or microRNAs [37] . In herpesvirus, this problem has not yet emerged. It is an essential aim to identify a target that is active in different virus isolates. Champier et al. [38] demonstrated by using sequence analysis of 25 HCMV strains and other herpesviruses that the gene UL89 has 12 regions that are identical or at least strongly similar. Although the target side of shRNA_A is located in the conserved region VI, the highly active shRNA_B is not located in a conserved part of UL89, but in a part that is a putative DNA binding domain (CT, data not shown).
In conclusion, our data presented in this study showed that two UL89-specific shRNAs can suppress gene expression and prevent viral maturation; therefore, an RNAi strategy using pUL89 as a target is a promising approach for antiviral therapy. For treatment of persistent HCMV infection, the constant supply of expressed siRNA is required. In this scenario, stable integration of shRNA using the lentiviral system will be a powerful tool for antiviral therapy of persistent infections. However, if cells are exposed to an exogenous molecule, such as shRNA, it might lead to dysfunction of normal cellular functions; therefore, the usage of RNAi has to be carefully controlled. Before clinical usage, problems concerning the delivery, safety and efficacy have to be solved. Nevertheless, the potential of RNAi therapy for specific gene targeting is a promising field for future therapeutics.
